{"success":true,"data":{"pressRelease":{"id":"155647","rtpr_id":"nGNXG7t25-20260929","ticker":"REPL","exchange":"NASDAQ","all_tickers":["REPL"],"title":"REPL Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in Replimune Group, Inc. Securities Class Action - Contact SueWallSt","author":"Globe Newswire","published_at":"2026-09-29T14:13:00.098Z","article_body":"NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- SueWallSt alerts investors in\nReplimune Group, Inc. (NASDAQ: REPL) of a pending securities class action on\nbehalf of purchasers between October 20, 2025 and April 10, 2026. Check if\nyou might be eligible to recover your investment losses\n(https://www.globenewswire.com/Tracker?data=Tv3WzSQ4t0aADCFVYd69DkwRir6ltalMwEy9GSmxIKjHPfkvrUI1HGqQC_Fh0reB_9PC8hqfvJIdM8HAqBLo68bq7G7rBrCitY6KROfWpCziUq7Xe1pCb9oP9mn1QgYcNhTGNLWvasWQs5LymVNCnFyL0UJcu7zhC7IIoTzAHblHOePpH29Xlw1J0BnNEQnzwBibGsEHZx4UYjrPjsUaR95QsBt__PNUWKw58w_Qxwb57fe2GuWzNp0oDwyY0FZk).\nYou may also contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com or (888)\nSueWallSt.\n\nShares closed at a Class Period high of $10.73 on December 8, 2025 and closed\nat $1.70 on April 13, 2026, an approximate decline of $9.03 per share, or\nroughly 84%. The Court has set October 5, 2026 as the deadline to apply for\nlead plaintiff appointment.\n\n\"Investors deserve transparency about material risks that could affect their\ninvestments. The complaint asserts that shareholders were not told the\nresubmission efficacy package rested on an early unplanned analysis of only 40\npatients.\" -- Joseph E. Levi, Esq.\n\nThe Alleged 40-Patient Resubmission Data Package\n\nManagement told the market in October 2025 that the FDA had accepted the RP1\nresubmission and considered it a complete response to the July 2025 complete\nresponse letter. The lawsuit asserts that what was not shared was the\ncomposition of the efficacy evidence: an early unplanned analysis from the\nRP1-104 (IGNYTE-3) study representing about 10% of the planned 400-patient\nenrollment. The FDA's April 10, 2026 letter stated that this data \"is\ninsufficient to support an efficacy claim.\"\n\nEvidentiary Standards in Accelerated Approval Submissions\n* The action claims the agency had recommended use of data from the ongoing\nPhase 3 trial to potentially support accelerated approval.\n* As alleged, an early unplanned interim analysis of 40 patients was submitted\ninstead.\n* The FDA also stated response criteria used in RPL-001-16 were not consistent\nwith RECIST v1.1.\n* The agency concluded RPL-001-16 was not an adequate and well-controlled\ninvestigation demonstrating substantial evidence of effectiveness.\n* The lawsuit asserts these deficiencies made rejection a foreseeable risk not\ndisclosed to shareholders.\n* Quarterly net losses of $83.1 million and $70.9 million were reported during\nClass Period quarters.\nWhy Data Adequacy Allegedly Matters to Investors\n\nThe action claims that positive characterizations of the resubmission's\ncompleteness allegedly inflated REPL's trading price, and that shares repriced\nsharply once the agency's findings became public.\n\nLearn more about the case\n(https://www.globenewswire.com/Tracker?data=A7yDTYsH60HdAA8tIp-04OXUmauUMpgCIuCVCcZ_8kjz1rkb18S9vfozNOf_brlFn9foz_m8JQNkzfpwzM4jlhEOP0v8RqHePB_YIby4N9Hs8ztCTuwZOEHjjtG25Pd8B-8R7sLd8mdxLyUAnfbhpTY-bYRk060o-yOOIEGQ0R0pHX7n_MZ8Q83m2QGfJdv_O5tgHU5LynPKf49zGs9wQw==)\nor call (888) SueWallSt.\n\nWHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky\nLLP has established itself as a nationally-recognized securities litigation\nfirm that has secured hundreds of millions of dollars for aggrieved\nshareholders and built a track record of winning high-stakes cases. The firm\nhas extensive expertise representing investors in complex securities\nlitigation and a team of over 70 employees to serve our clients. For seven\nyears in a row, Levi & Korsinsky has ranked in ISS Securities Class Action\nServices' Top 50 Report as one of the top securities litigation firms in the\nUnited States.\n\nFrequently Asked Questions About the REPL Lawsuit\n\nQ: Who is notifying investors about the REPL securities class action? A: Levi\n& Korsinsky, LLP is notifying investors that a securities class action has\nbeen filed on behalf of investors who purchased REPL securities during the\nclass period. The firm is nationally recognized, ranked in the ISS Top 50 for\nseven consecutive years, and has recovered hundreds of millions of dollars for\naggrieved investors.\n\nQ: Who is eligible to join the REPL investor lawsuit? A: Investors who\npurchased REPL stock or securities between October 20, 2025 and April 10, 2026\nand suffered financial losses may be eligible. Eligibility is based on\npurchase date and documented losses -- not on whether you still hold the\nshares.\n\nQ: What specific misstatements does the REPL lawsuit allege? A: The complaint\nalleges Replimune Group, Inc. made materially false or misleading statements\nregarding the adequacy of its RP1 clinical trial designs and the sufficiency\nof the data supporting its BLA resubmission during the Class Period. When the\nFDA's complete response letter rejecting the BLA was disclosed, the stock\nprice declined sharply.\n\nQ: What do REPL investors need to do right now? A: Investors may gather\nbrokerage records showing purchase dates, share quantities, and prices paid.\nNo immediate action is required to remain eligible as an absent class member.\n\nQ: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the\ninvestor appointed by the court to represent the entire class. Lead plaintiffs\nare typically investors with the largest documented losses. Being appointed\ndoes not increase individual recovery but gives direct oversight of how the\ncase is run.\n\nQ: What if I already sold my REPL shares -- can I still recover losses? A:\nYes. Eligibility is based on when you purchased, not whether you still hold\nthe shares. Investors who bought during the Class Period and sold at a loss\nmay still be eligible to participate.\n\nQ: What does it cost me to participate? A: There is no upfront cost to submit\nyour information and review whether you may be eligible to recover. Should you\nchoose to participate in the securities class action, they are generally\nhandled on a contingency basis, with any attorneys' fees and expenses subject\nto court approval.\n\nQ: What if Replimune Group, Inc. goes bankrupt before the case resolves? A:\nSecurities class action claims may survive bankruptcy in many circumstances.\nD&O insurance policies are frequently a potential source of settlement funds.\n\nCONTACT:\n\nLevi & Korsinsky, LLP\n\nJoseph E. Levi, Esq.\n\n33 Whitehall Street, 27th Floor\n\nNew York, NY 10004\n\njlevi@SueWallSt.com\n\nTel: (888) SueWallSt\n\nFax: (212) 363-7171\n\nAttorney Advertising. Prior results do not guarantee similar outcomes.\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXG7t25-20260929","title":"REPL Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in Replimune Group, Inc. Securities Class Action - Contact SueWallSt","author":"Globe Newswire","ticker":"REPL","created":"2026-09-29T14:13:00.098Z","tickers":["REPL"],"exchange":"NASDAQ","article_body":"NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- SueWallSt alerts investors in\nReplimune Group, Inc. (NASDAQ: REPL) of a pending securities class action on\nbehalf of purchasers between October 20, 2025 and April 10, 2026. Check if\nyou might be eligible to recover your investment losses\n(https://www.globenewswire.com/Tracker?data=Tv3WzSQ4t0aADCFVYd69DkwRir6ltalMwEy9GSmxIKjHPfkvrUI1HGqQC_Fh0reB_9PC8hqfvJIdM8HAqBLo68bq7G7rBrCitY6KROfWpCziUq7Xe1pCb9oP9mn1QgYcNhTGNLWvasWQs5LymVNCnFyL0UJcu7zhC7IIoTzAHblHOePpH29Xlw1J0BnNEQnzwBibGsEHZx4UYjrPjsUaR95QsBt__PNUWKw58w_Qxwb57fe2GuWzNp0oDwyY0FZk).\nYou may also contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com or (888)\nSueWallSt.\n\nShares closed at a Class Period high of $10.73 on December 8, 2025 and closed\nat $1.70 on April 13, 2026, an approximate decline of $9.03 per share, or\nroughly 84%. The Court has set October 5, 2026 as the deadline to apply for\nlead plaintiff appointment.\n\n\"Investors deserve transparency about material risks that could affect their\ninvestments. The complaint asserts that shareholders were not told the\nresubmission efficacy package rested on an early unplanned analysis of only 40\npatients.\" -- Joseph E. Levi, Esq.\n\nThe Alleged 40-Patient Resubmission Data Package\n\nManagement told the market in October 2025 that the FDA had accepted the RP1\nresubmission and considered it a complete response to the July 2025 complete\nresponse letter. The lawsuit asserts that what was not shared was the\ncomposition of the efficacy evidence: an early unplanned analysis from the\nRP1-104 (IGNYTE-3) study representing about 10% of the planned 400-patient\nenrollment. The FDA's April 10, 2026 letter stated that this data \"is\ninsufficient to support an efficacy claim.\"\n\nEvidentiary Standards in Accelerated Approval Submissions\n* The action claims the agency had recommended use of data from the ongoing\nPhase 3 trial to potentially support accelerated approval.\n* As alleged, an early unplanned interim analysis of 40 patients was submitted\ninstead.\n* The FDA also stated response criteria used in RPL-001-16 were not consistent\nwith RECIST v1.1.\n* The agency concluded RPL-001-16 was not an adequate and well-controlled\ninvestigation demonstrating substantial evidence of effectiveness.\n* The lawsuit asserts these deficiencies made rejection a foreseeable risk not\ndisclosed to shareholders.\n* Quarterly net losses of $83.1 million and $70.9 million were reported during\nClass Period quarters.\nWhy Data Adequacy Allegedly Matters to Investors\n\nThe action claims that positive characterizations of the resubmission's\ncompleteness allegedly inflated REPL's trading price, and that shares repriced\nsharply once the agency's findings became public.\n\nLearn more about the case\n(https://www.globenewswire.com/Tracker?data=A7yDTYsH60HdAA8tIp-04OXUmauUMpgCIuCVCcZ_8kjz1rkb18S9vfozNOf_brlFn9foz_m8JQNkzfpwzM4jlhEOP0v8RqHePB_YIby4N9Hs8ztCTuwZOEHjjtG25Pd8B-8R7sLd8mdxLyUAnfbhpTY-bYRk060o-yOOIEGQ0R0pHX7n_MZ8Q83m2QGfJdv_O5tgHU5LynPKf49zGs9wQw==)\nor call (888) SueWallSt.\n\nWHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky\nLLP has established itself as a nationally-recognized securities litigation\nfirm that has secured hundreds of millions of dollars for aggrieved\nshareholders and built a track record of winning high-stakes cases. The firm\nhas extensive expertise representing investors in complex securities\nlitigation and a team of over 70 employees to serve our clients. For seven\nyears in a row, Levi & Korsinsky has ranked in ISS Securities Class Action\nServices' Top 50 Report as one of the top securities litigation firms in the\nUnited States.\n\nFrequently Asked Questions About the REPL Lawsuit\n\nQ: Who is notifying investors about the REPL securities class action? A: Levi\n& Korsinsky, LLP is notifying investors that a securities class action has\nbeen filed on behalf of investors who purchased REPL securities during the\nclass period. The firm is nationally recognized, ranked in the ISS Top 50 for\nseven consecutive years, and has recovered hundreds of millions of dollars for\naggrieved investors.\n\nQ: Who is eligible to join the REPL investor lawsuit? A: Investors who\npurchased REPL stock or securities between October 20, 2025 and April 10, 2026\nand suffered financial losses may be eligible. Eligibility is based on\npurchase date and documented losses -- not on whether you still hold the\nshares.\n\nQ: What specific misstatements does the REPL lawsuit allege? A: The complaint\nalleges Replimune Group, Inc. made materially false or misleading statements\nregarding the adequacy of its RP1 clinical trial designs and the sufficiency\nof the data supporting its BLA resubmission during the Class Period. When the\nFDA's complete response letter rejecting the BLA was disclosed, the stock\nprice declined sharply.\n\nQ: What do REPL investors need to do right now? A: Investors may gather\nbrokerage records showing purchase dates, share quantities, and prices paid.\nNo immediate action is required to remain eligible as an absent class member.\n\nQ: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the\ninvestor appointed by the court to represent the entire class. Lead plaintiffs\nare typically investors with the largest documented losses. Being appointed\ndoes not increase individual recovery but gives direct oversight of how the\ncase is run.\n\nQ: What if I already sold my REPL shares -- can I still recover losses? A:\nYes. Eligibility is based on when you purchased, not whether you still hold\nthe shares. Investors who bought during the Class Period and sold at a loss\nmay still be eligible to participate.\n\nQ: What does it cost me to participate? A: There is no upfront cost to submit\nyour information and review whether you may be eligible to recover. Should you\nchoose to participate in the securities class action, they are generally\nhandled on a contingency basis, with any attorneys' fees and expenses subject\nto court approval.\n\nQ: What if Replimune Group, Inc. goes bankrupt before the case resolves? A:\nSecurities class action claims may survive bankruptcy in many circumstances.\nD&O insurance policies are frequently a potential source of settlement funds.\n\nCONTACT:\n\nLevi & Korsinsky, LLP\n\nJoseph E. Levi, Esq.\n\n33 Whitehall Street, 27th Floor\n\nNew York, NY 10004\n\njlevi@SueWallSt.com\n\nTel: (888) SueWallSt\n\nFax: (212) 363-7171\n\nAttorney Advertising. Prior results do not guarantee similar outcomes.\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-29T14:13:00.142615039Z","server_sent_at_ms":1790691180142},"received_at":"2026-09-29T14:13:00.268Z","source_url":null},"analysis":{"id":"144369","press_release_id":"155647","analysis_json":{"redFlags":["ongoing securities class action against the filer with alleged disclosure failures around RP1 BLA resubmission","FDA complete response letter rejected RP1 efficacy package based on 40-patient interim analysis","stock declined roughly 84% during the alleged class period"],"eventType":"legal_litigation","narrative":"Levi & Korsinsky (SueWallSt) issued a solicitation alerting REPL investors to an October 5, 2026 lead plaintiff deadline in a pending securities class action covering purchases between October 20, 2025 and April 10, 2026.\n\nThe complaint alleges Replimune misled investors about the adequacy of its RP1 BLA resubmission, which reportedly rested on an early unplanned analysis of only 40 of 400 planned patients; the FDA rejected the resubmission in April 2026 and the stock fell roughly 84% from its class-period high.\n\nThis is law-firm marketing, not an issuer disclosure or court action; the underlying rejection was already public, so treat as low-signal noise for the ticker.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation on already-public FDA rejection -- suppress."},"keyFigures":{"customDimensions":{"class_period":"October 20, 2025 - April 10, 2026","stock_decline_pct":"roughly 84%","planned_enrollment":400,"lead_plaintiff_deadline":"October 5, 2026","interim_analysis_patients":40}},"quotedText":"The FDA's April 10, 2026 letter stated that this data \"is insufficient to support an efficacy claim.\"","namedEntities":{"people":[{"name":"Joseph E. Levi, Esq.","role":"attorney, Levi & Korsinsky"}],"products":["RP1","IGNYTE-3 (RP1-104)"],"companies":[{"name":"Replimune Group, Inc.","ticker":"REPL","relationship":"class action target"},{"name":"Levi & Korsinsky, LLP","relationship":"plaintiff law firm"},{"name":"SueWallSt","relationship":"plaintiff law firm brand"}],"dollarAmounts":[{"amount":"$10.73","context":"class period high close, December 8, 2025"},{"amount":"$1.70","context":"closing price April 13, 2026"},{"amount":"$9.03","context":"approximate per-share decline"},{"amount":"$83.1 million","context":"quarterly net loss during class period"},{"amount":"$70.9 million","context":"quarterly net loss during class period"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm solicitation issued by Levi & Korsinsky (SueWallSt) reminding investors of the October 5, 2026 lead plaintiff deadline. No new issuer disclosure, no certified class, no settlement."},"tickerRelevance":{"others":[],"primary":"REPL"},"globalImportance":15,"audienceRelevance":12,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingNote":"underlying FDA rejection was prior news; this release is solicitation only"}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Levi & Korsinsky (SueWallSt) issued a solicitation alerting REPL investors to an October 5, 2026 lead plaintiff deadline in a pending securities class action covering purchases between October 20, 2025 and April 10, 2026.\n\nThe complaint alleges Replimune misled investors about the adequacy of its RP1 BLA resubmission, which reportedly rested on an early unplanned analysis of only 40 of 400 planned patients; the FDA rejected the resubmission in April 2026 and the stock fell roughly 84% from its class-period high.\n\nThis is law-firm marketing, not an issuer disclosure or court action; the underlying rejection was already public, so treat as low-signal noise for the ticker.","key_figures":{"customDimensions":{"class_period":"October 20, 2025 - April 10, 2026","stock_decline_pct":"roughly 84%","planned_enrollment":400,"lead_plaintiff_deadline":"October 5, 2026","interim_analysis_patients":40}},"named_entities":{"people":[{"name":"Joseph E. Levi, Esq.","role":"attorney, Levi & Korsinsky"}],"products":["RP1","IGNYTE-3 (RP1-104)"],"companies":[{"name":"Replimune Group, Inc.","ticker":"REPL","relationship":"class action target"},{"name":"Levi & Korsinsky, LLP","relationship":"plaintiff law firm"},{"name":"SueWallSt","relationship":"plaintiff law firm brand"}],"dollarAmounts":[{"amount":"$10.73","context":"class period high close, December 8, 2025"},{"amount":"$1.70","context":"closing price April 13, 2026"},{"amount":"$9.03","context":"approximate per-share decline"},{"amount":"$83.1 million","context":"quarterly net loss during class period"},{"amount":"$70.9 million","context":"quarterly net loss during class period"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-29T14:13:09.355Z","global_importance":15,"audience_relevance":12,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingNote":"underlying FDA rejection was prior news; this release is solicitation only"}},"durationMs":8660,"modelName":"glm-5.3-flashx"}}